Cefepime vs. Carbapenems for Treating AmpC β-lactamase-producing Enterobacteriaceae Bloodstream Infections
Completed
- Conditions
- Bacteremia
- Registration Number
- NCT05535751
- Lead Sponsor
- University Hospital, Strasbourg, France
- Brief Summary
Recent international recommendations suggest the use of carbapenem rather than cefepime in this situation, but with a low level of evidence, given the few existing studies. As cefepime is a less broad-spectrum antibiotic than carbapenems, its use would limit the selection of multidrug-resistant bacteria.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
- Patient who has expressed opposition to the reuse of their data for scientific research purposes.
- Resistance to Cefepime or carbapenems
- Multiple bacteremia
- Treatment with a molecule other than Cefepime or carbapenem.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hospital mortality 30 days after infection
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which cefepime inhibits AmpC β-lactamase-producing Enterobacteriaceae in bloodstream infections?
How does the comparative effectiveness of cefepime versus carbapenems in treating AmpC β-lactamase-producing Enterobacteriaceae bloodstream infections impact clinical outcomes and resistance patterns?
Which biomarkers could predict patient response to cefepime over carbapenems in AmpC β-lactamase-producing Enterobacteriaceae bacteremia?
What are the known adverse events associated with cefepime treatment for AmpC β-lactamase-producing Enterobacteriaceae bloodstream infections and how do they compare to carbapenems?
What combination therapies or alternative β-lactam antibiotics are being explored alongside cefepime for managing AmpC β-lactamase-producing Enterobacteriaceae infections?
Trial Locations
- Locations (1)
Service des maladies infectieuses et tropicales - CHU de Strasbourg - France
🇫🇷Strasbourg, France
Service des maladies infectieuses et tropicales - CHU de Strasbourg - France🇫🇷Strasbourg, France